7f8i
From Proteopedia
(Difference between revisions)
| (2 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
==Crystal structure of HPV6 L1 pentamer== | ==Crystal structure of HPV6 L1 pentamer== | ||
| - | <StructureSection load='7f8i' size='340' side='right'caption='[[7f8i]]' scene=''> | + | <StructureSection load='7f8i' size='340' side='right'caption='[[7f8i]], [[Resolution|resolution]] 3.37Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7F8I OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7F8I FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[7f8i]] is a 10 chain structure with sequence from [https://en.wikipedia.org/wiki/Human_papillomavirus_type_6 Human papillomavirus type 6]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7F8I OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7F8I FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7f8i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7f8i OCA], [https://pdbe.org/7f8i PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7f8i RCSB], [https://www.ebi.ac.uk/pdbsum/7f8i PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7f8i ProSAT]</span></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.366Å</td></tr> |
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7f8i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7f8i OCA], [https://pdbe.org/7f8i PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7f8i RCSB], [https://www.ebi.ac.uk/pdbsum/7f8i PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7f8i ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | == Function == | ||
| + | [https://www.uniprot.org/uniprot/Q9W9C6_9PAPI Q9W9C6_9PAPI] Forms an icosahedral capsid with a T=7 symmetry and a 50 nm diameter. The capsid is composed of 72 pentamers linked to each other by disulfide bonds and associated with L2 proteins. Binds to heparan sulfate proteoglycans on cell surface of basal layer keratinocytes to provide initial virion attachment. This binding mediates a conformational change in the virus capsid that facilitates efficient infection. The virion enters the host cell via endocytosis. During virus trafficking, L1 protein dissociates from the viral DNA and the genomic DNA is released to the host nucleus. The virion assembly takes place within the cell nucleus. Encapsulates the genomic DNA together with protein L2.[HAMAP-Rule:MF_04002][RuleBase:RU361248] | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | In vaccine development, broadly or cross-type neutralizing antibodies (bnAbs or cnAbs) are frequently targeted to enhance protection. Utilizing immunodominant antibodies could help fine-tune vaccine immunogenicity and augment the precision of immunization strategies. However, the methodologies to capitalize on the attributes of bnAbs in vaccine design have not been clearly elucidated. In this study, we discovered a cross-type neutralizing monoclonal antibody, 13H5, against human papillomavirus 6 (HPV6) and HPV11. This nAb exhibited a marked preference for HPV6, demonstrating superior binding activity to virus-like particles (VLPs) and significantly higher prevalence in anti-HPV6 human serum as compared to HPV11 antiserum (90% vs. 31%). Through co-crystal structural analysis of the HPV6 L1 pentamer:13H5 complex, we delineated the epitope as spanning four segments of amino acids (Phe42-Ala47, Gly172-Asp173, Glu255-Val275, and Val337-Tyr351) on the L1 surface loops. Further interaction analysis and site-directed mutagenesis revealed that the Ser341 residue in the HPV6 HI loop plays a critical role in the interaction between 13H5 and L1. Substituting Ser341 with alanine, which is the residue type present in HPV11 L1, almost completely abolished binding activity to 13H5. By swapping amino acids in the HPV11 HI loop with corresponding residues in HPV6 L1 (Ser341, Thr338, and Thr339), we engineered chimeric HPV11-6HI VLPs. Remarkably, the chimeric HPV11-6HI VLPs shifted the high immunodominance of 13H5 from HPV6 to the engineered VLPs and yielded comparable neutralization titers for both HPV6 and HPV11 in mice and non-human primates. This approach paves the way for the design of broadly protective vaccines from antibodies within the main immunization reservoir. | ||
| + | |||
| + | Rational design of a cross-type HPV vaccine through immunodominance shift guided by a cross-neutralizing antibody.,Wang Z, Wang D, Chen J, Gao F, Jiang Y, Yang C, Qian C, Chi X, Zhang S, Xu Y, Lu Y, Shen J, Zhang C, Li J, Zhou L, Li T, Zheng Q, Yu H, Li S, Xia N, Gu Y Sci Bull (Beijing). 2024 Feb 26;69(4):512-525. doi: 10.1016/j.scib.2023.12.021. , Epub 2023 Dec 9. PMID:38160175<ref>PMID:38160175</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 7f8i" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Human papillomavirus type 6]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Gu Y]] | [[Category: Gu Y]] | ||
Current revision
Crystal structure of HPV6 L1 pentamer
| |||||||||||
